Podcasts

Podcast: Biopharma’s evolving relationships with CDMOs

M&A, new modalities, and COVID-19 have all changed the way drug sponsors work with their third-party manufacturers, according to delegates from Samsung Biologics, Catalent, and AGC Biologics. The BioProcess Insider Expression Platform (BIEP) podcast is back, with an in-depth look at the evolving relationships between biopharma and their contract development and manufacturing organization (CDMO) partners. Recorded live from EBD’s BIO Europe Spring event last month, BioProcess Insider discussed the changing dynamic and reliance drug sponsors have with their CDMOs with:…

COVID drove innovation in consumables sourcing and inventory management

COVID-19 has changed how drugs and vaccines are made according to experts who say limited raw material supplies and manufacturing capacity have forced industry to innovate in sourcing and inventory management. The pandemic has disrupted the global supply of consumables and technologies according to Josh Speidel from Latham BioPharm Group, who said on BioProcess Insider’s recent State of the Industry webinar that delivery timelines have increased significantly. “The pandemic has put immense pressure on the global manufacturing capacity†adding that…

CPhI 2021: Back to business (almost) for Pharma trade shows

Milan, Italy is the place to be this week as over 20,000 pharma delegates shake off the past 20 months and attend CPhI Worldwide 2021. BioProcess Insider donned a facemask and presented its ‘Green Pass’ to attend the world’s largest pharma show, CPhI Worldwide in Milan. Naturally numbers were down on 2019’s event in Frankfurt, Germany but with over 1,300 exhibitors and more than 20,000 attendees it is fair to say that the appetite for face-to-face events among the life…

Podcast: Life beyond Provenge as Dendreon enters CDMO world

As Dendreon secures its first manufacturing deal, we speak with VP of corporate strategy about the firm’s new direction in the cell therapy CDMO space. Dendreon Pharmaceuticals will provide process development, end-to-end logistics, and scalable cGMP manufacturing support for Shoreline Biosciences’s pipeline of allogeneic natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC). Financials have not been disclosed but the deal marks the first contract announced by Dendreon since it relaunched itself as a contract…